Clinical Trials Logo

Nausea Post Chemotherapy clinical trials

View clinical trials related to Nausea Post Chemotherapy.

Filter by:
  • None
  • Page 1

NCT ID: NCT05272865 Not yet recruiting - Neoplasms Clinical Trials

Pharmacokinetic and Pharmacodynamic Evaluation of Formulations of Δ9-THC

Start date: August 15, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

Study based on the pharmacokinetic, pharmacodynamic, safety and stability evaluation of 3 standardized formulations of THC, to be used in healthy volunteers and post-chemotherapy patients as an adjuvant in the symptomatic treatment of the latter in discomfort associated with cancer treatment, with the aim of possible new therapeutic entities.

NCT ID: NCT04669132 Completed - Clinical trials for Nausea Post Chemotherapy

Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast Cancer

OLNEPA
Start date: December 17, 2020
Phase: Phase 2
Study type: Interventional

This is a longitudinal, one arm, prospective phase II study, designed to evaluate the efficacy of Olanzapine Netupitant and Palonosetron in the controll of nausea and vomiting induced by highly emetogenic chemotherapy.

NCT ID: NCT04141514 Recruiting - Vomiting Clinical Trials

Effects of Short-term Therapeutic Fasting on Nausea and Vomiting Due to Chemotherapy

CHEMO-FAST
Start date: January 20, 2022
Phase: N/A
Study type: Interventional

This study aims to estimate the effect of the practice of a short-term partial fasting compared to a usual alimentation on nausea and vomiting within 5 days after the start of a chemotherapy session on 2 successive chemotherapy courses (4 sessions of chemotherapy) in patients starting treatment with highly emetogenic chemotherapy (ABVD or AVD protocol).

NCT ID: NCT03996863 Withdrawn - Clinical trials for Chemotherapy-induced Nausea and Vomiting

Prevention of Unmitigated Chemotherapy-induced Emesis

PUCE
Start date: August 1, 2019
Phase: N/A
Study type: Interventional

Chemotherapy-induced nausea and vomiting (CINV) remains a major obstacle to patient care and continues to decrease quality of life. Despite the addition of medications and antiemetic regimens, doctors' ability to control CINV is still inadequate: even moderately-emetogenic chemotherapy regimens cause roughly 20% of patients to have vomiting and over 40% to experience significant nausea. In this study, the investigators test a transcranial vibrating system that has shown great promise at reducing nausea and vomiting. .

NCT ID: NCT03572829 Completed - Vomiting Clinical Trials

Aprepitant for Nause and Vomiting Induced by Chemoradiotherapy in HNSCC

Start date: March 1, 2018
Phase: Phase 2
Study type: Interventional

To evaluate the safety and efficacy of aprepitant combined with ondansetron and dexamethasone to prevent nausea and vomiting induced by Intensity-modulated Radiotherapy (IMRT) cisplatin-chemotherapy regimen in locally advanced squamous cell carcinoma of head and neck

NCT ID: NCT03478605 Recruiting - Nausea Clinical Trials

Trial to Evaluate Efficacy of Olanzapine With Short-acting 5HT3 Inhibitors in Chemotherapy-induced Nausea & Vomiting (CINV) Prophylaxis

OlaCINV
Start date: May 25, 2018
Phase: Phase 2
Study type: Interventional

Olanzapine-containing regimens for CINV prophylaxis may provide even better protection than aprepitant-containing regimens.

NCT ID: NCT01504711 Completed - Clinical trials for Gastrointestinal Cancer

Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy

Start date: June 2012
Phase: N/A
Study type: Interventional

This clinical trial studies fosaprepitant dimeglumine in preventing nausea and vomiting in patients with gastrointestinal cancer receiving combination chemotherapy. Antiemetic drugs, such as fosaprepitant dimeglumine, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy.